[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-001", "question": "A 45-year-old male presents with syncope. ECG shows sinus rhythm with first-degree AV block and a right bundle branch block. Echocardiogram reveals a left ventricular ejection fraction (LVEF) of 42% with mild LV dilation. Genetic testing confirms a pathogenic variant in the LMNA gene (Lamin A/C). He has no history of sustained ventricular tachycardia. Which of the following is the most appropriate management?", "options": ["Implantation of a dual-chamber pacemaker", "Implantation of an implantable cardioverter-defibrillator (ICD)", "Implantation of an implantable loop recorder", "Initiation of Amiodarone", "Initiation of Metoprolol and reassessment of LVEF in 3 months"], "answer": "B", "answer_index": 1, "explanation": "Lamin A/C (LMNA) cardiomyopathy carries a disproportionately high risk of malignant ventricular arrhythmias and sudden cardiac death, often independent of the degree of LV dysfunction. Current guidelines recommend ICD implantation for patients with an LMNA mutation and risk factors such as AV block, male sex, or non-missense mutations, even if the LVEF is >35%. A pacemaker alone addresses the conduction disease but leaves the patient unprotected against the high risk of fatal ventricular arrhythmias.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with syncope, a reduced LVEF (42%), mild LV dilation, and a pathogenic variant in the LMNA gene. LMNA gene mutations are associated with dilated cardiomyopathy and increased risk of arrhythmias, including ventricular tachycardia and sudden cardiac death. Despite no history of sustained ventricular tachycardia, the presence of a reduced LVEF (<35% is the typical threshold for primary prevention ICD, but this patient has a reduced LVEF and a known genetic predisposition to arrhythmias) and symptoms (syncope) in the context of a cardiomyopathy warrants consideration for an ICD.\n\nOption A: A dual-chamber pacemaker is indicated for symptomatic bradycardia or AV block. While the patient has first-degree AV block, it is not causing his syncope, and the primary concern is the risk of ventricular arrhythmias.\nOption B: An ICD is indicated for primary or secondary prevention of sudden cardiac death due to ventricular arrhythmias. Given the reduced LVEF, LV dilation, and the LMNA gene mutation which predisposes to arrhythmias, an ICD is the most appropriate intervention to prevent sudden cardiac death, even in the absence of documented sustained VT. Syncope in this context could be due to ventricular arrhythmias.\nOption C: An implantable loop recorder is used for diagnosing infrequent arrhythmias. While it could help identify the cause of syncope, the genetic diagnosis and reduced LVEF already point to a high risk of life-threatening arrhythmias, making definitive treatment more appropriate than further diagnostic monitoring.\nOption D: Amiodarone is an antiarrhythmic medication that can be used to suppress ventricular arrhythmias. However, it has significant side effects and is generally not the first-line treatment for primary prevention of sudden cardiac death in patients with reduced LVEF and cardiomyopathy, especially when an ICD is a more definitive preventative measure.\nOption E: Metoprolol is a beta-blocker that can be beneficial in heart failure and can help manage symptoms and potentially improve LVEF. However, it does not directly address the risk of sudden cardiac death from ventricular arrhythmias, which is the primary concern in this patient with a genetic predisposition. Reassessing LVEF is important, but it doesn't negate the immediate risk.\n\nConsidering the patient's reduced LVEF, LV dilation, and the LMNA gene mutation, the most significant risk is sudden cardiac death from ventricular arrhythmias. Therefore, an ICD is the most appropriate management to prevent this.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-002", "question": "A 68-year-old male presents with a 3-week history of brief, involuntary jerking movements of his right face and arm, occurring up to 40 times per day. He remains conscious during these events. Interictal EEG and brain MRI are unremarkable. He is beginning to show signs of short-term memory impairment. Which of the following is the most appropriate initial treatment?", "options": ["Levetiracetam", "Carbamazepine", "Intravenous Methylprednisolone", "Tissue Plasminogen Activator (tPA)", "Haloperidol"], "answer": "C", "answer_index": 2, "explanation": "The clinical presentation is classic for faciobrachial dystonic seizures (FBDS), which are pathognomonic for Anti-LGI1 encephalitis (a form of limbic encephalitis). These seizures are characteristically resistant to standard anti-epileptic drugs but respond dramatically to immunotherapy (steroids, IVIG). Early recognition and treatment with immunotherapy are crucial to prevent the progression to severe cognitive impairment and full-blown limbic encephalitis.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient presents with focal motor seizures affecting the right face and arm, which are brief and involuntary. He remains conscious during these events, suggesting a focal onset aware seizure. The onset of these seizures and the developing short-term memory impairment in a 68-year-old male raise concern for an underlying structural lesion, even though the initial MRI is unremarkable. However, given the focal nature of the seizures, antiepileptic drugs are the mainstay of treatment.\n\nLet's analyze the options:\n\nA. Levetiracetam: This is a broad-spectrum antiepileptic drug that is effective for focal seizures and is often a first-line choice due to its favorable side effect profile and efficacy.\n\nB. Carbamazepine: This is another effective antiepileptic drug for focal seizures, particularly those originating from the temporal lobe. However, it can have more side effects than levetiracetam, such as dizziness, ataxia, and hyponatremia.\n\nC. Intravenous Methylprednisolone: This is a corticosteroid used to treat inflammatory conditions. It is not indicated for the treatment of epilepsy unless there is an underlying inflammatory cause of the seizures, which is not suggested by the presentation.\n\nD. Tissue Plasminogen Activator (tPA): This is a thrombolytic agent used to treat acute ischemic stroke. It is not relevant to the management of seizures.\n\nE. Haloperidol: This is an antipsychotic medication used to treat psychosis. It is not an antiepileptic drug and would not be appropriate for seizure management.\n\nConsidering the options, levetiracetam is a highly appropriate initial treatment for focal motor seizures. While carbamazepine is also a possibility, levetiracetam is often preferred as a first-line agent due to its generally better tolerability. The unremarkable MRI does not rule out a subtle lesion, and the developing cognitive impairment warrants prompt seizure control.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-003", "question": "A 55-year-old female is admitted to the ICU with sepsis and severe malnutrition. She has a history of chronic back pain managed with acetaminophen. Arterial blood gas shows pH 7.26, pCO2 28 mmHg, HCO3 12 mEq/L. Serum chemistry shows Na 140, Cl 104, BUN 18, Cr 0.8. Lactate is 1.1 mmol/L. Serum ketones are negative. Measured serum osmolality is 295 mOsm/kg (calculated 290). Which of the following is the most likely etiology of her metabolic acidosis?", "options": ["Methanol intoxication", "D-lactic acidosis", "Pyroglutamic acidosis (5-oxoproline accumulation)", "Propylene glycol toxicity", "Salicylate toxicity"], "answer": "C", "answer_index": 2, "explanation": "The patient has a high anion gap metabolic acidosis (AG = 24) with a normal lactate, no ketones, normal renal function, and a normal osmol gap (ruling out toxic alcohols like methanol or propylene glycol). The combination of chronic acetaminophen use, sepsis, and malnutrition leads to glutathione depletion, causing a disruption in the gamma-glutamyl cycle and accumulation of 5-oxoproline (pyroglutamic acid). This is an under-recognized cause of high anion gap acidosis in this specific patient population.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient presents with a severe metabolic acidosis (low pH, low HCO3) with a normal anion gap (Na - Cl - HCO3 = 140 - 104 - 12 = 24, which is within the normal range of 8-16, but considering the low bicarbonate, a normal anion gap is more likely if the unmeasured anions are not significantly elevated. However, the question asks for the etiology of the metabolic acidosis, and the provided values are key). Let's analyze the options:\n\nA. Methanol intoxication: Typically causes a high anion gap metabolic acidosis due to formic acid accumulation. Ketones are usually positive.\n\nB. D-lactic acidosis: Can occur in patients with short bowel syndrome or other conditions affecting gut flora. It typically presents with a normal anion gap metabolic acidosis. However, the lactate level is only 1.1 mmol/L, which is not significantly elevated and doesn't strongly suggest lactic acidosis.\n\nC. Pyroglutamic acidosis (5-oxoproline accumulation): This can occur in patients with malnutrition, sepsis, liver disease, or those on chronic acetaminophen use, especially in the setting of glutathione depletion. It typically presents with a normal anion gap metabolic acidosis. The patient has severe malnutrition, sepsis, and a history of chronic acetaminophen use, all of which are risk factors. The measured osmolality being slightly higher than calculated can sometimes be seen with accumulation of unmeasured osmoles, though this is not a definitive finding for pyroglutamic acidosis.\n\nD. Propylene glycol toxicity: Can cause a high anion gap metabolic acidosis and sometimes an elevated calculated osmolality gap. Ketones are usually negative. While the patient has negative ketones, the anion gap is not clearly elevated, and propylene glycol is not a common cause in this context without a clear exposure history.\n\nE. Salicylate toxicity: Typically causes a mixed acid-base disorder, often starting with respiratory alkalosis followed by a high anion gap metabolic acidosis. Ketones can be positive.\n\nConsidering the patient's clinical presentation (sepsis, severe malnutrition, chronic acetaminophen use) and the laboratory findings (normal anion gap metabolic acidosis, normal lactate, negative ketones), pyroglutamic acidosis is the most likely etiology. The chronic acetaminophen use can deplete glutathione, making the patient susceptible to 5-oxoproline accumulation, especially in the context of sepsis and malnutrition.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-004", "question": "A 34-year-old male presents with progressive dyspnea. He has a BMI of 17 kg/m2. Chest radiography shows apical pleural thickening. High-resolution CT demonstrates upper-lobe predominant subpleural fibrosis and a flattened chest configuration ('platythorax'). He has no history of asbestos exposure or connective tissue disease. Which of the following is the most likely diagnosis?", "options": ["Idiopathic Pulmonary Fibrosis (IPF)", "Pleuroparenchymal Fibroelastosis (PPFE)", "Chronic Hypersensitivity Pneumonitis", "Lymphangioleiomyomatosis (LAM)", "Pulmonary Alveolar Proteinosis"], "answer": "B", "answer_index": 1, "explanation": "Pleuroparenchymal Fibroelastosis (PPFE) is a rare idiopathic interstitial pneumonia characterized by fibrosis of the visceral pleura and subpleural lung parenchyma, predominantly in the upper lobes. The radiographic hallmark is the 'platythorax' (flattening of the chest cage) due to fibrosis progression. This contrasts with IPF (lower lobe predominant) and Hypersensitivity Pneumonitis (mosaic attenuation, centrilobular nodules).", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with progressive dyspnea, low BMI, apical pleural thickening, upper-lobe predominant subpleural fibrosis, and a flattened chest configuration. These findings are highly suggestive of Pleuroparenchymal Fibroelastosis (PPFE).\n\nLet's consider why the other options are less likely:\n\n*   **A. Idiopathic Pulmonary Fibrosis (IPF):** IPF typically shows a lower-lobe predominant pattern of fibrosis, often with honeycombing. While it can cause dyspnea and fibrosis, the upper-lobe predominance and specific findings like apical pleural thickening and platythorax are not characteristic of IPF.\n*   **C. Chronic Hypersensitivity Pneumonitis (CHP):** CHP can cause fibrosis, but it often has a more diffuse distribution or is associated with centrilobular nodules and ground-glass opacities, particularly in the mid-to-upper lung zones. The prominent subpleural fibrosis and apical pleural thickening are less typical.\n*   **D. Lymphangioleiomyomatosis (LAM):** LAM is a rare disease that affects women and is characterized by cystic lung changes, typically in the lower lobes. It is not associated with pleural thickening or upper-lobe predominant fibrosis.\n*   **E. Pulmonary Alveolar Proteinosis (PAP):** PAP is characterized by the accumulation of lipoproteinaceous material in the alveoli, leading to diffuse alveolar opacities, often described as a \"crazy-paving\" pattern on CT. It does not typically present with pleural thickening or subpleural fibrosis.\n\nPPFE is a rare interstitial lung disease characterized by fibrosis predominantly in the subpleural regions of the upper lobes, often associated with pleural thickening and a flattened chest. The clinical presentation and imaging findings described in the question are classic for PPFE.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-005", "question": "A 24-year-old African American male presents with cyanosis and shortness of breath after taking dapsone for a skin lesion. Pulse oximetry reads 85% and does not improve with supplemental oxygen. Arterial blood gas shows a normal PaO2 but methemoglobin level is 18%. He has a known history of hemolysis after ingesting fava beans. Which of the following is the most appropriate treatment?", "options": ["Methylene Blue 1 mg/kg IV", "Ascorbic Acid (Vitamin C) IV", "Hydroxocobalamin IV", "Hyperbaric Oxygen Therapy", "Sodium Thiosulfate IV"], "answer": "B", "answer_index": 1, "explanation": "The patient has methemoglobinemia precipitated by dapsone. However, his history of hemolysis with fava beans strongly suggests Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. Methylene blue is contraindicated in G6PD deficiency because it requires NADPH (generated by G6PD) to reduce methemoglobin; without G6PD, methylene blue is ineffective and can induce severe hemolysis. Ascorbic acid (Vitamin C) or exchange transfusion is the appropriate management.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient presents with cyanosis, shortness of breath, and a significantly elevated methemoglobin level (18%) after taking dapsone. This is a classic presentation of methemoglobinemia. The fact that pulse oximetry does not improve with supplemental oxygen is also characteristic, as pulse oximeters cannot accurately distinguish between oxyhemoglobin and methemoglobin. The history of hemolysis after ingesting fava beans suggests a potential underlying G6PD deficiency, which can predispose individuals to dapsone-induced methemoglobinemia.\n\nLet's evaluate the treatment options:\n\nA. Methylene Blue 1 mg/kg IV: Methylene blue is the first-line antidote for methemoglobinemia when the level is significantly elevated (typically >20-30% or symptomatic). It acts as an electron acceptor, facilitating the reduction of methemoglobin back to hemoglobin. Given the patient's symptoms and methemoglobin level of 18%, methylene blue is indicated.\n\nB. Ascorbic Acid (Vitamin C) IV: Ascorbic acid can be used as a second-line treatment for methemoglobinemia, particularly in cases of G6PD deficiency where methylene blue is contraindicated or ineffective. It acts as a reducing agent, but its effect is slower and less potent than methylene blue. While the patient has a history suggestive of G6PD deficiency, methylene blue is still the preferred initial treatment for symptomatic methemoglobinemia at this level.\n\nC. Hydroxocobalamin IV: Hydroxocobalamin is primarily used for cyanide poisoning. It binds to cyanide ions to form cyanocobalamin, which is then excreted. It is not indicated for methemoglobinemia.\n\nD. Hyperbaric Oxygen Therapy: Hyperbaric oxygen therapy is used for conditions like decompression sickness, carbon monoxide poisoning, and certain infections. It is not a treatment for methemoglobinemia.\n\nE. Sodium Thiosulfate IV: Sodium thiosulfate is used as an antidote for cyanide poisoning, often in combination with sodium nitrite. It acts as a sulfur donor to facilitate the detoxification of cyanide. It is not indicated for methemoglobinemia.\n\nConsidering the patient's presentation of symptomatic methemoglobinemia with a methemoglobin level of 18%, methylene blue is the most appropriate and immediate treatment. While G6PD deficiency is a consideration, methylene blue is still the first-line therapy unless there is a contraindication or failure of response.\n\nThe answer is (A)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-006", "question": "A 14-year-old boy with a history of exercise-induced syncope is diagnosed with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) confirmed by an RyR2 mutation. He is compliant with high-dose Nadolol. A repeat exercise stress test shows a reduction in arrhythmia burden, but he still develops runs of bidirectional ventricular tachycardia at peak exertion. Which of the following is the best next step in management?", "options": ["Switch Nadolol to Metoprolol Succinate", "Add Flecainide", "Perform Radiofrequency Ablation of the ventricular focus", "Implant a dual-chamber pacemaker", "Add Verapamil"], "answer": "B", "answer_index": 1, "explanation": "In patients with CPVT who have breakthrough arrhythmias despite optimal beta-blocker therapy (preferably Nadolol or Propranolol), the addition of Flecainide is the guideline-recommended next step. Flecainide has a direct blocking effect on the cardiac ryanodine receptor (RyR2), addressing the underlying mechanism. Radiofrequency ablation is generally ineffective due to the polymorphic/multifocal nature of the arrhythmia.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "The patient has CPVT, confirmed by an RyR2 mutation, and is experiencing residual bidirectional ventricular tachycardia at peak exertion despite high-dose Nadolol. This indicates that Nadolol alone is insufficient to fully control his arrhythmias.\n\nLet's analyze the options:\n\nA. Switch Nadolol to Metoprolol Succinate: Metoprolol is a beta-blocker, but Nadolol is a non-selective beta-blocker with intrinsic sympathomimetic activity, which is generally preferred in CPVT due to its longer duration of action and potential for better control. Switching to Metoprolol Succinate, another beta-blocker, is unlikely to provide superior control if high-dose Nadolol is already failing.\n\nB. Add Flecainide: Flecainide is a Class Ic antiarrhythmic. While it can be effective in some forms of ventricular tachycardia, it is generally not the first-line agent for CPVT, especially in the context of an RyR2 mutation. In fact, some studies suggest that flecainide can worsen outcomes in CPVT.\n\nC. Perform Radiofrequency Ablation of the ventricular focus: Radiofrequency ablation is typically reserved for cases of CPVT that are refractory to medical therapy and where a specific, identifiable focus can be targeted. In CPVT, the arrhythmia is often triggered by catecholamines and can arise from multiple sites, making ablation challenging and often not curative. However, in cases of persistent symptoms despite optimal medical therapy, ablation might be considered if a dominant focus can be identified.\n\nD. Implant a dual-chamber pacemaker: Pacemakers are not indicated for the primary management of CPVT. While they can help with rate control in some arrhythmias, they do not address the underlying catecholamine-induced triggers of CPVT.\n\nE. Add Verapamil: Verapamil is a calcium channel blocker. While beta-blockers are the cornerstone of CPVT management, calcium channel blockers, particularly verapamil, have shown efficacy in patients with CPVT who remain symptomatic despite optimal beta-blocker therapy. Verapamil can help to reduce calcium overload in the sarcoplasmic reticulum, which is implicated in the arrhythmogenesis of CPVT. It is often used as an add-on therapy in refractory cases.\n\nGiven that the patient is still experiencing runs of bidirectional ventricular tachycardia at peak exertion despite high-dose Nadolol, adding Verapamil is the most appropriate next step in medical management to further suppress the arrhythmias. If medical therapy remains insufficient, then ablation might be considered, but it's not the immediate next step.\n\nThe final answer is $\\boxed{E}$."}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-007", "question": "A 26-year-old female with a history of sensorineural hearing loss and short stature presents with acute onset aphasia and right-sided hemiparesis. MRI shows a T2-hyperintense lesion in the left temporal lobe that does not conform to a vascular territory. Serum lactate is elevated. Which of the following agents is indicated for the acute management of this condition?", "options": ["Intravenous Tissue Plasminogen Activator (tPA)", "Intravenous Arginine", "Intravenous Heparin", "High-dose Aspirin", "Plasma Exchange"], "answer": "B", "answer_index": 1, "explanation": "The clinical picture (stroke-like episode not respecting vascular territories, hearing loss, elevated lactate) is classic for MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes). The stroke-like episodes are due to metabolic failure and microvascular angiopathy (nitric oxide deficiency), not thrombotic occlusion. Intravenous Arginine is the recommended acute treatment to improve nitric oxide availability and cerebral blood flow. tPA is not indicated and could be harmful.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "The patient presents with acute neurological deficits (aphasia and hemiparesis) and a T2-hyperintense lesion in the brain. The lesion not conforming to a vascular territory, along with the history of sensorineural hearing loss and short stature, suggests a potential underlying metabolic or genetic disorder rather than a typical ischemic stroke. The elevated serum lactate further supports a metabolic derangement.\n\nLet's analyze the options:\n\nA. Intravenous Tissue Plasminogen Activator (tPA): tPA is indicated for acute ischemic stroke. However, the lesion not conforming to a vascular territory makes a typical ischemic stroke less likely. Furthermore, certain underlying conditions can increase the risk of hemorrhagic transformation with tPA.\n\nB. Intravenous Arginine: Arginine is an amino acid that plays a role in nitric oxide synthesis. While nitric oxide is important for vascular function, intravenous arginine is not a standard acute management for neurological deficits of this nature, especially without a clear diagnosis of a specific arginine-related disorder.\n\nC. Intravenous Heparin: Heparin is an anticoagulant used to prevent or treat blood clots. While a clot could cause stroke-like symptoms, the atypical lesion location and other clinical features make a simple embolic or thrombotic stroke less probable as the primary diagnosis.\n\nD. High-dose Aspirin: Aspirin is an antiplatelet agent. Similar to heparin, it's used in stroke management, but the atypical presentation raises concerns about its primary indication here.\n\nE. Plasma Exchange: Plasma exchange (plasmapheresis) is a procedure that removes and replaces a patient's plasma. It is indicated for a variety of conditions, including certain autoimmune diseases, thrombotic microangiopathies, and some metabolic disorders where circulating toxins or antibodies contribute to the pathology. Given the constellation of symptoms (neurological deficits, atypical lesion, elevated lactate, and potential underlying genetic/metabolic predisposition suggested by short stature and hearing loss), a condition treatable with plasma exchange is a strong consideration. For example, certain inherited metabolic disorders or autoimmune conditions affecting the central nervous system could present this way and be amenable to plasma exchange.\n\nConsidering the atypical presentation and the need to address a potential underlying systemic issue contributing to the neurological deficit, plasma exchange is the most appropriate choice among the given options for acute management, as it can remove harmful substances from the circulation.\n\nThe answer is (E)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-008", "question": "A 32-year-old female is evaluated for palpitations. Labs reveal a TSH of 7.2 mIU/L (High) and Free T4 of 2.9 ng/dL (High). An MRI of the pituitary shows a 5mm hypoenhancing lesion. Sex Hormone Binding Globulin (SHBG) levels are elevated. Which of the following is the most likely diagnosis?", "options": ["Resistance to Thyroid Hormone (RTH) beta", "TSH-secreting pituitary adenoma (TSHoma)", "Graves' disease", "Familial Dysalbuminemic Hyperthyroxinemia", "Heterophile antibody interference"], "answer": "B", "answer_index": 1, "explanation": "Both RTH and TSHoma present with inappropriate TSH secretion (high T4, non-suppressed TSH). The key differentiator is the peripheral tissue response. In TSHoma, peripheral tissues (like the liver) are sensitive to the high thyroid hormone levels, resulting in elevated markers of thyroid action such as Sex Hormone Binding Globulin (SHBG). In RTH, the peripheral tissues are resistant, so SHBG levels are typically normal. The pituitary lesion supports TSHoma, but incidentalomas are common; the metabolic profile (high SHBG) confirms the diagnosis.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with palpitations, elevated TSH (7.2 mIU/L), and elevated Free T4 (2.9 ng/dL). This pattern of elevated TSH and elevated Free T4 is characteristic of a TSH-secreting pituitary adenoma (TSHoma). The presence of a pituitary lesion on MRI further supports this diagnosis. Elevated Sex Hormone Binding Globulin (SHBG) is also a common finding in hyperthyroid states, including those caused by TSHomas.\n\nLet's consider why the other options are less likely:\n\nA. Resistance to Thyroid Hormone (RTH) beta: In RTH, there is a defect in the thyroid hormone receptor, leading to a paradoxical elevation of both TSH and thyroid hormones. However, RTH is typically associated with normal or slightly elevated TSH, and the presence of a pituitary lesion on MRI is not a characteristic feature.\n\nC. Graves' disease: Graves' disease is an autoimmune disorder that causes hyperthyroidism. It is characterized by elevated Free T4 and suppressed TSH. The elevated TSH in this patient makes Graves' disease unlikely.\n\nD. Familial Dysalbuminemic Hyperthyroxinemia: This is a benign genetic condition where there is an increased binding of thyroid hormone to albumin, leading to elevated total T4 and T3 levels, but with normal Free T4 and suppressed TSH. This patient has elevated Free T4 and elevated TSH, so this is not consistent.\n\nE. Heterophile antibody interference: Heterophile antibodies can interfere with immunoassay measurements, leading to falsely elevated or decreased results. While this is a possibility for any lab test, the combination of clinical symptoms (palpitations), consistent laboratory findings (elevated TSH and Free T4), and the presence of a pituitary lesion on MRI makes a TSHoma a much more specific and likely diagnosis.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-009", "question": "A 48-year-old male who works as a tool grinder presents with chronic dry cough and dyspnea. Bronchoalveolar lavage (BAL) reveals multinucleated giant cells that appear to be engulfing other cells ('cannibalistic' giant cells). Which of the following exposures is most likely responsible for this finding?", "options": ["Silica", "Asbestos", "Cobalt", "Beryllium", "Coal dust"], "answer": "C", "answer_index": 2, "explanation": "The presence of 'cannibalistic' multinucleated giant cells in BAL or biopsy is pathognomonic for Hard Metal Lung Disease (Giant Cell Interstitial Pneumonia). This is caused by exposure to Cobalt, often in the form of tungsten carbide alloy used in tool grinding, diamond polishing, or saw sharpening. Beryllium causes granulomas similar to sarcoidosis, not GIP.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The question describes a patient with a chronic cough and dyspnea, and importantly, bronchoalveolar lavage (BAL) findings of multinucleated giant cells that appear to be engulfing other cells ('cannibalistic' giant cells). This specific description of giant cells is characteristic of a reaction to certain inhaled foreign materials.\n\nLet's consider the options:\n\nA. Silica: Exposure to silica dust can lead to silicosis, a fibrotic lung disease. While giant cells can be seen in silicosis, the 'cannibalistic' description is not the most prominent feature.\n\nB. Asbestos: Asbestos exposure can cause asbestosis, mesothelioma, and lung cancer. Asbestos bodies, which are ferruginous bodies, are characteristic findings in BAL or lung biopsy in asbestosis. Multinucleated giant cells can be present, but the 'cannibalistic' description is not the hallmark.\n\nC. Cobalt: Cobalt exposure, particularly in hard metal lung disease (often seen in diamond polishers and tool grinders), is known to cause a granulomatous interstitial pneumonitis. Multinucleated giant cells are a common finding in this condition, and they can exhibit phagocytosis of other cells, leading to the 'cannibalistic' appearance. This is a strong contender.\n\nD. Beryllium: Beryllium exposure can lead to berylliosis, a granulomatous lung disease. Giant cells are seen in berylliosis, but the 'cannibalistic' description is not as specifically associated with it as with cobalt.\n\nE. Coal dust: Coal dust exposure leads to coal worker's pneumoconiosis (CWP), also known as black lung disease. The characteristic finding in CWP is the coal macule and progressive massive fibrosis. While macrophages and some giant cells can be present, the 'cannibalistic' giant cells are not a defining feature.\n\nGiven the occupational history of a tool grinder and the specific description of 'cannibalistic' multinucleated giant cells in BAL, cobalt exposure leading to hard metal lung disease is the most likely cause.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-010", "question": "A 52-year-old male presents to the ED 2 hours after ingesting a massive overdose of sustained-release Verapamil. He is hypotensive (BP 60/40 mmHg) and bradycardic (HR 38 bpm). He remains hypotensive despite 3 liters of crystalloid, IV Calcium Gluconate, and IV Glucagon. Which of the following is the most appropriate next therapeutic intervention?", "options": ["High-dose Insulin Euglycemia therapy", "Transvenous Pacing", "Hemodialysis", "IV Amiodarone", "IV Lipid Emulsion (20%)"], "answer": "A", "answer_index": 0, "explanation": "High-dose Insulin Euglycemia (HIE) is the recommended therapy for severe calcium channel blocker toxicity refractory to initial measures (fluids, calcium). Insulin has a positive inotropic effect and improves myocardial glucose utilization in the stressed heart. While lipid emulsion is a salvage therapy, HIE has stronger evidence as a first-line pharmacologic support after calcium/fluids. Transvenous pacing often fails to capture or improve cardiac output in severe CCB poisoning due to global myocardial depression.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient has a massive sustained-release verapamil overdose presenting with severe hypotension and bradycardia refractory to initial treatments like crystalloids, calcium gluconate, and glucagon. Verapamil is a calcium channel blocker that inhibits cardiac contractility and conduction, leading to these symptoms.\n\nLet's analyze the options:\n\nA. High-dose Insulin Euglycemia therapy (HIE): This is a well-established antidote for calcium channel blocker overdose. Insulin has positive inotropic and chronotropic effects independent of glucose levels, and it can improve myocardial function and overcome the blockade of calcium channels.\n\nB. Transvenous Pacing: While pacing can address bradycardia, it may not be effective in severe verapamil overdose because the drug's toxicity affects myocardial contractility directly, not just the electrical conduction system. Furthermore, the hypotension is likely due to impaired contractility, which pacing alone won't fix.\n\nC. Hemodialysis: Verapamil is not effectively removed by hemodialysis due to its high protein binding and large volume of distribution.\n\nD. IV Amiodarone: Amiodarone is an antiarrhythmic that can also prolong the QT interval and has negative inotropic effects, which could worsen the patient's condition. It is not indicated for verapamil overdose.\n\nE. IV Lipid Emulsion (20%): While IV lipid emulsion is an antidote for local anesthetic systemic toxicity and some other lipophilic drug overdoses, its efficacy in verapamil overdose is less established and generally considered a second-line or adjunctive therapy if HIE is not effective or available.\n\nGiven the refractory hypotension and bradycardia despite standard treatments, high-dose insulin euglycemia therapy is the most appropriate next step as it directly addresses the mechanism of verapamil toxicity.\n\nThe answer is (A)"}]